Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms [0.03%]
低甲基化药物治疗的骨髓衰竭疾病中分子预后体系的应用价值评估
Kelly S Chien,Ziyi Li,Luca Lanino et al.
Kelly S Chien et al.
RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma [0.03%]
生发中心滤泡淋巴瘤中IGH重排与RAG1/RAG2表达及转化相关的研究
Silvia Lonardi,Valeria Cancila,Gaia Morello et al.
Silvia Lonardi et al.
Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia [0.03%]
通过恢复IKAROS在GLUT1表达和糖酵解中的活性来增强酪氨酸激酶抑制剂对费城染色体阳性急性淋巴细胞白血病的敏感性
Linyao Zhang,Qi Han,Huimin Xiang et al.
Linyao Zhang et al.
Many patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are still less sensitive to tyrosine kinase inhibitors (TKIs). Ph+ ALL shows a high incidence of IKZF1 deletions. Casein kinase II (CK2)-mediated hyp...
Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry [0.03%]
边缘区淋巴瘤的患者特征及治疗结果：德国前瞻性MZL注册研究结果
Alexander Grunenberg,Birgit Schmelzle,Jacqueline Gökeler et al.
Alexander Grunenberg et al.
Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis [0.03%]
关于MUSASHI2-DEPTOR-KIF11轴调控代谢适应和白血病发展的订正论文
Tania Setiawan,Jabir Aliyu Muhammad,Nadya Marcelina Julianto et al.
Tania Setiawan et al.
Published Erratum
Leukemia. 2026 Mar 5. DOI:10.1038/s41375-026-02909-2 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing [0.03%]
SRSF2突变相关的异常红细胞生成与由于FYN剪接错误导致的mTORC1信号增强有关
Jonas S Jutzi,Edie Crosse,Chulwoo J Kim et al.
Jonas S Jutzi et al.
Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on ...
Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia [0.03%]
纠正：基于外周血流式细胞术的浆细胞白血病定义
Arwa Bohra,Rafla Hassan,Saurabh Zanwar et al.
Arwa Bohra et al.
Published Erratum
Leukemia. 2026 Feb 25. DOI:10.1038/s41375-026-02897-3 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms [0.03%]
TP53突变的骨髓增生性肿瘤患者的危险分层
Benjamin Rolles,Cilomar Martins de Oliveira Filho,Nathan Fergusson et al.
Benjamin Rolles et al.
While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we an...
Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia [0.03%]
替扎坎勒库尔治疗B细胞急性淋巴细胞白血病失败的儿童、青少年和年轻人的特点及结局决定因素
Nicolas Lecornec,Florence Rabian,Marie-Emilie Dourthe et al.
Nicolas Lecornec et al.
Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). Ho...
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images [0.03%]
基于数字化骨髓活检图像的人工智能鉴别增生期原发性骨髓纤维化与特发性血小板增多症
Andrew Srisuwananukorn,Giuseppe Gaetano Loscocco,James M Dolezal et al.
Andrew Srisuwananukorn et al.
Prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET) are distinct myeloproliferative neoplasms (MPNs) with overlapping clinical features, often leading to diagnostic uncertainty. We developed an artificial intellige...